Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of HL-032 after oral administration in healthy male volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: HanAll BioPharma Co., Ltd.

Criteria

Inclusion Criteria:

• Healthy male subjects

• Age(yr)between 19 and 50

• Signed written informed consent

Exclusion Criteria:

• Known hypersensitivity to Octreotide or hGH(human growth hormone)

• History of Cardiovascular, Respiratory, Renal/Genitourinary, Gastrointestinal, Neurological/Psychic, cancer

• Alcoholic, smokers or drug abusers

• Other conditions which in the opinion of the investigator preclude enrollment into the study